Study · Randomized controlled trial · n = 1,438 · 2025

6 results

Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials.

Horn DB, Kahan S, Batterham RL, Cao D, Lee CJ, Murphy M, Gonsahn-Bollie S, Chigutsa F, Stefanski A, Dunn JP

Clinical obesity12 Jan 2025Cited by 12 (Europe PMC)

PMID39800653PMCIDPMC12096058DOI10.1111/cob.12734PepBankPUB-39800653

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialOther
In adults with obesity or overweight on tirzepatide in SURMOUNT-1, median time to weight plateau was longer in BMI class II and III than in overweight.
In plain wordsIn adults on tirzepatide, people with higher starting BMI took longer to reach a weight plateau.
Peptide
Tirzepatide
Outcome
Not applicableMedian time to weight plateau by BMI category (SURMOUNT-1)
Study
n = 1,438
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Median TTWP
24.3 weeks
overweight
Median TTWP
26 weeks
class I
Median TTWP
36.1 weeks
class II
Median TTWP
36.1 weeks
class III
Source sentences
Summary
Across BMI categories (overweight, class I, II, and III), median TTWP in SURMOUNT-1 was 24.3, 26.0, 36.1, and 36.1 weeks, respectively (p <.05, class II and III vs. overweight).
2 context sentences(design, population, supporting numbers)
Summary · context
We investigated factors associated with time to weight plateau (TTWP) in tirzepatide-treated participants with obesity or overweight in a post-hoc analysis of SURMOUNT-1 and SURMOUNT-4 trials.
Summary · context
Participants adherent to tirzepatide treatment and achieving ≥5% weight loss by primary endpoint (week 72 SURMOUNT-1; week 88 SURMOUNT-4) were included.
Report a problemFND-3980065301
02HumanRandomized controlled trialOther
In adults with obesity or overweight on tirzepatide in SURMOUNT-1, most participants had reached a weight plateau by week 72 in every BMI category.
In plain wordsIn adults on tirzepatide, most people reached a stable weight by week 72, whatever their starting BMI.
Peptide
Tirzepatide
Outcome
Not applicableProportion reaching weight plateau by week 72 (SURMOUNT-1)
Study
n = 1,438
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Reached weight plateau
90.2%
overweight
Reached weight plateau
88.9%
class I
Reached weight plateau
87.6%
class II
Reached weight plateau
87.8%
class III
Source sentences
Summary
By week 72, 90.2%, 88.9%, 87.6%, and 87.8% of participants in SURMOUNT-1 had reached a weight plateau across respective BMI categories [Correction added on 22 January 2025, after first online publication: The "72%" has been changed to "72" in this version.].
3 context sentences(design, population, supporting numbers)
Summary · context
In this post-hoc analysis, most participants reached a weight plateau by week 72.
Summary · context
We investigated factors associated with time to weight plateau (TTWP) in tirzepatide-treated participants with obesity or overweight in a post-hoc analysis of SURMOUNT-1 and SURMOUNT-4 trials.
Summary · context
Participants adherent to tirzepatide treatment and achieving ≥5% weight loss by primary endpoint (week 72 SURMOUNT-1; week 88 SURMOUNT-4) were included.
Report a problemFND-3980065302
03HumanRandomized controlled trialOther
In adults with obesity or overweight on tirzepatide, SURMOUNT-4 results for time to weight plateau were similar to those in SURMOUNT-1.
In plain wordsIn adults on tirzepatide, a second trial showed similar results for how long it took weight loss to level off.
Peptide
Tirzepatide
Outcome
Not applicableTime to weight plateau in SURMOUNT-4
Study
n = 259
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Results in SURMOUNT-4 were similar.
2 context sentences(design, population, supporting numbers)
Summary · context
We investigated factors associated with time to weight plateau (TTWP) in tirzepatide-treated participants with obesity or overweight in a post-hoc analysis of SURMOUNT-1 and SURMOUNT-4 trials.
Summary · context
Participants adherent to tirzepatide treatment and achieving ≥5% weight loss by primary endpoint (week 72 SURMOUNT-1; week 88 SURMOUNT-4) were included.
Report a problemFND-3980065306
04HumanRandomized controlled trialOther
In adults with obesity or overweight, higher tirzepatide doses were associated with a longer time to weight plateau.
In plain wordsIn adults on tirzepatide, higher doses were linked to a longer time before weight loss levelled off.
Peptide
Tirzepatide
Outcome
IncreaseTime to weight plateau by tirzepatide dose
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
10/15 mg versus lower dosesAs given in this study (human).
Source sentences
Summary
Higher doses of tirzepatide
2 context sentences(design, population, supporting numbers)
Summary · context
We investigated factors associated with time to weight plateau (TTWP) in tirzepatide-treated participants with obesity or overweight in a post-hoc analysis of SURMOUNT-1 and SURMOUNT-4 trials.
Summary · context
Participants adherent to tirzepatide treatment and achieving ≥5% weight loss by primary endpoint (week 72 SURMOUNT-1; week 88 SURMOUNT-4) were included.
Report a problemFND-3980065303
05HumanRandomized controlled trialOther
In adults with obesity or overweight on tirzepatide, younger age was associated with a longer time to weight plateau.
In plain wordsIn adults on tirzepatide, younger people took longer before weight loss levelled off.
Peptide
Tirzepatide
Outcome
Not applicableTime to weight plateau by age
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
younger age, and female sex were associated with a longer TTWP.
2 context sentences(design, population, supporting numbers)
Summary · context
We investigated factors associated with time to weight plateau (TTWP) in tirzepatide-treated participants with obesity or overweight in a post-hoc analysis of SURMOUNT-1 and SURMOUNT-4 trials.
Summary · context
Participants adherent to tirzepatide treatment and achieving ≥5% weight loss by primary endpoint (week 72 SURMOUNT-1; week 88 SURMOUNT-4) were included.
Report a problemFND-3980065304
06HumanRandomized controlled trialOther
In adults with obesity or overweight on tirzepatide, female sex was associated with a longer time to weight plateau.
In plain wordsIn adults on tirzepatide, women took longer than men before weight loss levelled off.
Peptide
Tirzepatide
Outcome
Not applicableTime to weight plateau by sex
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
female sex were associated with a longer TTWP.
2 context sentences(design, population, supporting numbers)
Summary · context
We investigated factors associated with time to weight plateau (TTWP) in tirzepatide-treated participants with obesity or overweight in a post-hoc analysis of SURMOUNT-1 and SURMOUNT-4 trials.
Summary · context
Participants adherent to tirzepatide treatment and achieving ≥5% weight loss by primary endpoint (week 72 SURMOUNT-1; week 88 SURMOUNT-4) were included.
Report a problemFND-3980065305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT04660643

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss

Eli Lilly and Companyn = 78329 Mar 2021 to 18 May 2023

Obesity · Overweight

Trial page ClinicalTrials.govUpdated 22 May 2024

CompletedPhase 3Results postedNCT04184622

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

Eli Lilly and Companyn = 2,5394 Dec 2019 to 6 Jul 2024

Overweight · Obesity

Trial page ClinicalTrials.govUpdated 24 Jul 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.